Eclipse Ventures Portfolio holdings
Eclipse Ventures is a venture capital firm whose pitch is that legacy industries must modernize how they operate to stay competitive. Its founder, Lior Susan, spent eight years in the Israel Defense Forces and then sold a company he had helped his brother build before launching the firm. Eclipse also incubates startups of its own, and in 2023 it raised one fund for early-stage companies and another for growth-stage ones, including some that had never raised outside capital. Its backing includes Bright Machines, which works to connect all the components of a factory to one central control system, and Enovix, a maker of lithium-ion batteries for small devices.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cerebras Systems
CBRS
|
+$2.69B |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 98.28% |
| 2 | Healthcare | 1.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Cerebras Systems
CBRS
$22.2B
| $2.53B | 98.28% |
+11,446,270
| New | +$2.69B |
2026 Q2
0 quarters
|
|
2
Owlet
OWLT
$127M
| $44.2M | 1.72% |
7,700,835
| – | – |
2021 Q4
18 quarters
|
|
Similar funds
Eclipse Ventures's Q2 2026 Portfolio in Review
As of Q2 2026, Eclipse Ventures held 2 positions worth $2.57B, up 6,402% from $39.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Eclipse Ventures deployed $2.69B of net new capital in Q2 2026, opening 1 new position. Its largest new stake was Cerebras Systems: 11,446,270 shares worth $2.53B.
By sector, the portfolio is most concentrated in Technology at 98% of assets, followed by Healthcare.
- Eclipse Ventures's largest Q2 2026 buy was Cerebras Systems: 11,446,270 shares worth $2.53B.
- Eclipse Ventures's ten largest holdings make up 100% of its $2.57B portfolio in Q2 2026.
- Eclipse Ventures opened 1 new position and closed 0 in Q2 2026.
- Eclipse Ventures's portfolio value rose 6,402% quarter-over-quarter to $2.57B.
Based on Eclipse Ventures's 13F filing for Q2 2026, filed 7 Aug 2026.